Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
出版年份 2020 全文链接
标题
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
作者
关键词
-
出版物
Frontiers in Pharmacology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-12-28
DOI
10.3389/fphar.2020.598308
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Biobanking for COVID-19 research
- (2021) Patrizia ROVERE-QUERINI et al. PANMINERVA MEDICA
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout
- (2020) Viola Klück et al. ANNALS OF THE RHEUMATIC DISEASES
- A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors
- (2020) Sukhvir Kaur et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
- (2020) Qiurong Ruan et al. INTENSIVE CARE MEDICINE
- Autophagy and Protein Secretion
- (2020) Giulio Cavalli et al. JOURNAL OF MOLECULAR BIOLOGY
- Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia
- (2020) Ning Tang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series
- (2020) Achille Aouba et al. ANNALS OF THE RHEUMATIC DISEASES
- COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
- (2020) Serena Colafrancesco et al. AUTOIMMUNITY REVIEWS
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
- (2020) Evangelos J. Giamarellos-Bourboulis et al. Cell Host & Microbe
- Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
- (2020) George Dimopoulos et al. Cell Host & Microbe
- Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients
- (2020) Xiaohua Chen et al. CLINICAL INFECTIOUS DISEASES
- Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
- (2020) Ruggero Capra et al. European Journal of Internal Medicine
- Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation
- (2020) Marcel Levi European Journal of Internal Medicine
- Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy
- (2020) Valentina Morena et al. European Journal of Internal Medicine
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
- (2020) Corrado Campochiaro et al. European Journal of Internal Medicine
- Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
- (2020) Yang Cao et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
- (2020) Emanuele Pontali et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tocilizumab treatment in COVID-19: A single center experience
- (2020) Pan Luo et al. JOURNAL OF MEDICAL VIROLOGY
- Elevated Interleukin‐6 and Severe COVID‐19: A Meta‐Analysis
- (2020) Muhammad Aziz et al. JOURNAL OF MEDICAL VIROLOGY
- COVID‐19 pneumonia treated with Sarilumab: a clinical series of eight patients
- (2020) Maurizio Benucci et al. JOURNAL OF MEDICAL VIROLOGY
- Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infection
- (2020) Simona Di Giambenedetto et al. JOURNAL OF MEDICAL VIROLOGY
- Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
- (2020) Marc Feldmann et al. LANCET
- COVID-19: consider cytokine storm syndromes and immunosuppression
- (2020) Puja Mehta et al. LANCET
- Effective treatment of severe COVID-19 patients with tocilizumab
- (2020) Xiaoling Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
- (2020) Yonggang Zhou et al. National Science Review
- Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli
- (2020) Emanuel Della-Torre et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
- (2020) Emanuel Della-Torre et al. ANNALS OF THE RHEUMATIC DISEASES
- Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy
- (2020) Evgeny V. Fominskiy et al. BLOOD PURIFICATION
- Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy
- (2020) Fabio Ciceri et al. CLINICAL IMMUNOLOGY
- Pharmaco-Immunomodulatory Therapy in COVID-19
- (2020) John G. Rizk et al. DRUGS
- Early administration of Interleukin-6 inhibitors for patients with severe Covid-19 disease is associated with decreased intubation, reduced mortality, and increased discharge
- (2020) Pranay Sinha et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study
- (2020) Fabrizio Cantini et al. JOURNAL OF INFECTION
- Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up
- (2020) Lang Wang et al. JOURNAL OF INFECTION
- Low prevalence of arrhythmias in clinically stable COVID‐19 patients
- (2020) Simone Sala et al. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY
- COVID-19: pharmacology and kinetics of viral clearance
- (2020) Nicola Farina et al. PHARMACOLOGICAL RESEARCH
- Baricitinib: A Review of Pharmacology, Safety, and Emerging Clinical Experience in COVID‐19
- (2020) Sarah C.J. Jorgensen et al. PHARMACOTHERAPY
- Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID‐19: A Case Series
- (2020) Iris Navarro‐Millán et al. Arthritis & Rheumatology
- Targeting GM-CSF in COVID-19 Pneumonia: Rationale and Strategies
- (2020) Aldo Bonaventura et al. Frontiers in Immunology
- Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients
- (2020) Serena Colafrancesco et al. Frontiers in Immunology
- Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies
- (2020) Yujun Tang et al. Frontiers in Immunology
- The COVID-19 Cytokine Storm; What We Know So Far
- (2020) Dina Ragab et al. Frontiers in Immunology
- Current treatment options and safety considerations when treating adult-onset Still’s disease
- (2020) Giulio Cavalli et al. Expert Opinion On Drug Safety
- IL‐18 and infections: Is there a role for targeted therapies?
- (2020) Alessandra Vecchié et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
- (2020) Qian Zhang et al. SCIENCE
- Autoantibodies against type I IFNs in patients with life-threatening COVID-19
- (2020) Paul Bastard et al. SCIENCE
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
- (2019) Chiara Crotti et al. DRUGS
- Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
- (2019) Esraa M. Eloseily et al. Arthritis & Rheumatology
- GM-CSF-Dependent Inflammatory Pathways
- (2019) John A. Hamilton Frontiers in Immunology
- Management of cytokine release syndrome related to CAR-T cell therapy
- (2019) Hongli Chen et al. Frontiers of Medicine
- Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease
- (2019) Corrado Campochiaro et al. ANNALS OF THE RHEUMATIC DISEASES
- MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile
- (2018) Waleed H. Mahallawi et al. CYTOKINE
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
- (2018) Alessandro Tomelleri et al. Frontiers in Immunology
- Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition
- (2018) Giacomo De Luca et al. ANNALS OF INTERNAL MEDICINE
- GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
- (2018) Rosalie M. Sterner et al. BLOOD
- Anakinra Therapy for Non-cancer Inflammatory Diseases
- (2018) Giulio Cavalli et al. Frontiers in Pharmacology
- Alarmins: Feel the Stress
- (2017) Peleg Rider et al. JOURNAL OF IMMUNOLOGY
- Acute Respiratory Distress Syndrome
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Trial of Tocilizumab in Giant-Cell Arteritis
- (2017) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still’s Disease: A Multicentre Retrospective Observational Study
- (2017) Serena Colafrancesco et al. Frontiers in Pharmacology
- Interleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
- (2017) Giulio Cavalli et al. Frontiers in Immunology
- Tocilizumab in patients with multisystem Erdheim–Chester disease
- (2017) Alvise Berti et al. OncoImmunology
- Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating Life-Threatening Myocarditis by Blocking Interleukin-1*
- (2016) Giulio Cavalli et al. CRITICAL CARE MEDICINE
- Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome
- (2016) Bita Shakoory et al. CRITICAL CARE MEDICINE
- Immunotherapeutic implications of IL-6 blockade for cytokine storm
- (2016) Toshio Tanaka et al. Immunotherapy
- Macrophage activation syndrome in the era of biologic therapy
- (2016) Alexei A. Grom et al. Nature Reviews Rheumatology
- Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression ofHLA-A*02:01in vivo
- (2016) Masahiro Hayashi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MHC class II super-enhancer increases surface expression of HLA-DR and HLA-DQ and affects cytokine production in autoimmune vitiligo
- (2016) Giulio Cavalli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborat
- (2016) Angelo Ravelli et al. Arthritis & Rheumatology
- Comparative Safety of Interleukin-1 Blockade With Anakinra in Patients With ST-Segment Elevation Acute Myocardial Infarction (from the VCU-ART and VCU-ART2 Pilot Studies)
- (2015) Antonio Abbate et al. AMERICAN JOURNAL OF CARDIOLOGY
- Treating Pulmonary Silicosis by Blocking Interleukin 1
- (2015) Giulio Cavalli et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity
- (2015) Alvise Berti et al. AUTOIMMUNITY REVIEWS
- Pivotal Roles of GM-CSF in Autoimmunity and Inflammation
- (2015) Aoi Shiomi et al. MEDIATORS OF INFLAMMATION
- Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies
- (2015) Giulio Cavalli et al. RHEUMATOLOGY
- Efficacy and safety of biological agents in adult-onset Still’s disease
- (2015) G Cavalli et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
- (2012) Fabrizio De Benedetti et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
- (2011) G. R. Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
- (2011) C. A. Dinarello BLOOD
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- Immunological and Inflammatory Functions of the Interleukin-1 Family
- (2009) Charles A. Dinarello Annual Review of Immunology
- Pulmonary alveolar proteinosis, a primary immunodeficiency of impaired GM-CSF stimulation of macrophages
- (2009) Bruce C Trapnell et al. CURRENT OPINION IN IMMUNOLOGY
- Modulation of TNF- -converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF- production and facilitates viral entry
- (2008) S. Haga et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started